Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Upadacitinib Versus Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Four Body Regions: Analysis From the Heads-Up Study.
Thyssen JP, Rosmarin D, Costanzo A, Warren R, Chu CY, Chovatiya R, Ladizinski B, Hu X, Liu Y, Calimlim B, Nduaka C, Vigna N, Armstrong A. Thyssen JP, et al. Among authors: vigna n. Dermatology. 2024 Oct 30:1-17. doi: 10.1159/000542275. Online ahead of print. Dermatology. 2024. PMID: 39476813 Free article.
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.
Guttman-Yassky E, Silverberg JI, Thaçi D, Papp KA, Ständer S, Beck LA, Kim BS, Hu X, Liu J, Calimlim BM, Vigna N, Crowley JT, Teixeira HD, Thyssen JP. Guttman-Yassky E, et al. Among authors: vigna n. J Eur Acad Dermatol Venereol. 2023 Dec;37(12):2558-2568. doi: 10.1111/jdv.19391. Epub 2023 Aug 26. J Eur Acad Dermatol Venereol. 2023. PMID: 37528500 Clinical Trial.
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials.
Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Mendes-Bastos P, et al. Among authors: vigna n. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15. J Am Acad Dermatol. 2022. PMID: 35714786 Free article. Clinical Trial.
The results of pollicization for congenital thumb hypoplasia.
Tonkin MA, Boyce DE, Fleming PP, Filan SL, Vigna N. Tonkin MA, et al. Among authors: vigna n. J Hand Surg Eur Vol. 2015 Jul;40(6):620-4. doi: 10.1177/1753193414535177. Epub 2014 May 23. J Hand Surg Eur Vol. 2015. PMID: 24859992
A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents.
Wagner KD, Redden L, Kowatch RA, Wilens TE, Segal S, Chang K, Wozniak P, Vigna NV, Abi-Saab W, Saltarelli M. Wagner KD, et al. Among authors: vigna nv. J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):519-532. doi: 10.1097/CHI.0b013e31819c55ec. J Am Acad Child Adolesc Psychiatry. 2009. PMID: 19325497 Clinical Trial.
Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder.
Redden L, DelBello M, Wagner KD, Wilens TE, Malhotra S, Wozniak P, Vigna NV, Greco N 4th, Kovacs X, Abi-Saab W, Saltarelli M; Depakote ER Pediatric Mania Group. Redden L, et al. Among authors: vigna nv. J Child Adolesc Psychopharmacol. 2009 Feb;19(1):83-9. doi: 10.1089/cap.2008.0106. J Child Adolesc Psychopharmacol. 2009. PMID: 19232026 Clinical Trial.
11 results